Method for selecting patients for treatment with an egfr inhibitor
AssigneeHospital District of Southwest Finland
InventorsOlli CARPEN, Minnamaija LINTUNEN, Raija RISTAMAKI, Jari SUNDSTROM, Annika ALGARS
Life of this patent
Estimating the term…
Abstract
The present invention relates to cancer diagnostics and therapies and to the detection of alterations in cancer cells that are diagnostic, prognostic or predictive. In particular, the present invention provides a method for detecting and analyzing whether a patient suffering from a cancer is responsive to the treatment with an EGFR inhibitor. In the method, a tissue section from a cancer sample is subjected to assays based on immunohistochemistry and enzymatic metallography.
Claims24
A method for detecting and analyzing whether a patient suffering from a cancer is responsive or non-responsive to the treatment with an EGFR inhibitor, the method comprising the steps of
- determining in a tissue section from a tumor sample obtained from said patient
- (i) the expression level of an EGFR protein in said tissue section by immunohistochemistry (IHC), and
- (ii) the level of EGFR gene copy number or the level of copy number of chromosome 7 by enzymatic metallography,
- wherein the area of highest expression of EGFR in a tissue section from said tumor sample is determined by IHC based on staining intensity, and said area of highest expression in the tumor sample is used in enzymatic metallography to determine gene copy number of EGFR gene or chromosome 7;
- and
- selecting said patient for treatment with said EGFR inhibitor,
- if the tumor sample of said patient displays expression of EGFR protein and an amplified copy number of the EGFR gene or chromosome 7.
Dependencies are inferred from the claim text.